Four Years Later, What's the Damage from the IRA's Drug Price Controls?

Four years after the Inflation Reduction Act introduced price controls on prescription drugs, early data shows significant reductions in pharmaceutical R&D, especially for small-molecule drugs and post-approval trials, potentially undermining drug innovation. Lawmakers are considering expanding the law despite these impacts, which could further discourage development of new and improved therapies.

This Wire brief sits within Fusion42's coverage of Biotech.